Evidence map›Paper›PMID 30353228›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Ourania Nicolatou-Galitis, Maria Kouri, Erofili Papadopoulou, Emmanouil Vardas, Dimitra Galiti, Joel B Epstein, Sharon Elad, Giuseppina Campisi, Nikolaos Tsoukalas, Kivanc Bektas-Kayhan and 5 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. MASCC/ISOO Clinical Practice Statement: imaging and clinical laboratory tests in the diagnosis and management of medication-related osteonecrosis of the jaw.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

Ourania Nicolatou-GalitisDental School, National and Kapodistrian University of Athens, Bouboulinas 41, N. Psyhico, 154 51, Athens, Greece. nicolatou.galitis@hotmail.com.
Maria KouriDental School, National and Kapodistrian University of Athens, Bouboulinas 41, N. Psyhico, 154 51, Athens, Greece.
Erofili PapadopoulouDental School, National and Kapodistrian University of Athens, Bouboulinas 41, N. Psyhico, 154 51, Athens, Greece.
Emmanouil VardasDental School, National and Kapodistrian University of Athens, Bouboulinas 41, N. Psyhico, 154 51, Athens, Greece.
Dimitra GalitiDental School, National and Kapodistrian University of Athens, Bouboulinas 41, N. Psyhico, 154 51, Athens, Greece.
Joel B EpsteinSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health System, Los Angeles CA and City of Hope National Medical Center, Duarte, CA, USA.
Sharon EladEastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA.
Giuseppina CampisiSector of Oral Medicine "V. Margiotta", Department Di.Chir.On.S, University of Palermo, Palermo, Italy.
Nikolaos TsoukalasConsultant Medical Oncologist, Oncology Department, Veterans Hospital (NIMTS), Athens, Greece.
Kivanc Bektas-KayhanFaculty of Dentistry, Department of Oral and Maxillofacial Surgery, Istanbul University, Istanbul, Turkey.
Winston TanHematology/Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
Jean-Jacques BodyCHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Cesar MiglioratiDepartment of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, USA.
Rajesh V LallaSection of Oral Medicine, University of Connecticut School of Dental Medicine, Farmington, CT, USA.
MASCC Bone Study Group
National and Kapodistrian University of Athens · GRCity Of Hope National Medical Center · USNIMTS Hospital · GRUniversité Libre de Bruxelles · BEUniversity of Connecticut · USMayo Clinic in Florida · USUniversity of Rochester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing.

objectiveTo review characteristics of ONJ in cancer patients receiving non-antiresorptives.

methodsA systematic review of the literature between 2009 and 2017 was conducted by the Bone Study Group of MASCC/ISOO.

resultsOf 6249 articles reviewed and from personal communication, 42 ONJ cases related to non-antiresorptives were identified. No gender predilection was noted. Median age was 60 years and ONJ stage 2 was most common, with predilection for posterior mandible. Exposed bone, pain, and infection were common at diagnosis. In comparison to bone targeting agents (BTAs), radiology, histology, and management were similar, with medication often discontinued. Delayed diagnosis (median 8 weeks) was noted. Important differences included earlier time to ONJ onset (median 20 weeks), absence of trigger event (40%), and greater likelihood of healing and shorter healing time (median 8 weeks) as compared to BTA-related ONJ. Gastrointestinal cancers predominated, followed by renal cell carcinomas compared to breast, followed by prostate cancers in BTA-related ONJ, reflecting different medications.

conclusionsData about non-antiresorptive-related ONJ is sparse. This type of ONJ may have better prognosis compared to the BTA-related ONJ, suggested by greater likelihood of healing and shorter healing time. However, the delay in diagnosis highlights the need for more education. This is the first attempt to characterize ONJ associated with different non-antiresorptives, including BRAF and immune checkpoint inhibitors.

Indexed as

AdultAgedBisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsDiphosphonatesFemaleHumansJawMaleMiddle AgedOsteonecrosisBone Density Conservation AgentsDiphosphonatesBone resorptionBRAF inhibitorsCytotoxic chemotherapyImmune checkpoint inhibitorsInhibitors of angiogenesismTOR inhibitorsOsteonecrosis of the jawTyrosine kinase inhibitors

Identifiers

PMID30353228
OpenAlexW2896518140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.